CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是测试是否延长口服抗病毒治疗改善标准IV抗病毒治疗后单纯疱疹病毒性脑炎[HSE]的长期结果。正在研究的具体问题包括： 1-长期口服伐昔洛韦能改善HSE的预后吗？ 2-当长期服用高剂量伐昔洛韦治疗HSE时，身体如何吸收、代谢和消除？ 3-HSE后的神经系统结果与中枢神经系统中单纯疱疹病毒的数量之间是否存在关系？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose of this study is to test whether prolonged oral antiviral therapy improves long term outcome of herpes simplex encephalitis [HSE] following standard IV antiviral treatment. Specific questions being looked at are: 1- Does long term oral valacyclovir improve outcomes in HSE? 2- How does the body absorb, metabolize, and eliminate high dose oral valacyclovir when used long term for HSE? 3- Is there a relationship between neurologic outcomes following HSE and the amount of Herpes Simplex virus in the Central Nervous System?